GLPGF (Lakefront Biotherapeutics NV) Cyclically Adjusted PB Ratio: (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLPGF Lakefront Biotherapeutics NV GLPGF
58 GF Score
Price $26.24
GF Value $118.63
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lakefront Biotherapeutics NV  (OTCPK:GLPGF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lakefront Biotherapeutics NV Cyclically Adjusted PB Ratio Related Terms


Lakefront Biotherapeutics NV Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Cyclically Adjusted PB Ratio Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.26 1.49 1.16 0.74 0.72

Lakefront Biotherapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.77 0.72 0.65 0.00

GLPGF vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakefront Biotherapeutics NV Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio falls into.


GLPGF
58GF Score
Lakefront Biotherapeutics NV GLPGF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lakefront Biotherapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lakefront Biotherapeutics NV's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=56.173/138.0500*138.0500
=56.173

Current CPI (Jun. 2026) = 138.0500.

Lakefront Biotherapeutics NV Quarterly Data

Book Value per Share CPI Adj_Book
201609 17.199 102.118 23.251
201612 17.302 102.614 23.277
201703 17.299 103.972 22.969
201706 23.613 103.902 31.373
201709 0.000 104.170 0.000
201712 23.512 104.804 30.970
201803 21.644 105.419 28.344
201806 20.154 106.063 26.232
201809 25.534 106.618 33.062
201812 25.363 107.252 32.646
201903 24.325 107.876 31.129
201906 23.566 107.896 30.152
201909 45.068 107.470 57.892
201912 49.410 108.065 63.120
202003 48.414 108.550 61.571
202006 47.859 108.540 60.871
202009 48.889 108.441 62.238
202012 49.664 108.511 63.184
202103 49.091 109.522 61.878
202106 48.975 110.305 61.294
202109 46.990 111.543 58.157
202112 45.564 114.705 54.837
202203 44.400 118.620 51.673
202206 42.569 120.948 48.588
202209 40.460 124.120 45.001
202212 40.645 126.578 44.329
202303 41.668 126.528 45.462
202306 42.483 125.973 46.556
202309 42.458 127.083 46.122
202312 46.263 128.292 49.782
202403 47.753 130.552 50.496
202406 47.540 130.691 50.217
202409 48.213 130.968 50.820
202412 46.033 132.346 48.017
202503 45.081 134.348 46.323
202506 46.275 133.495 47.854
202509 43.584 133.740 44.989
202512 57.500 135.070 58.769
202603 57.076 136.560 57.699
202606 56.173 138.050 56.173

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of $26.24 is trading 77.9% below its estimated GF Value™ of $118.63. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for GLPGF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $118.63 vs. price of $26.24 (77.9% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
58GF Score

Get the complete analysis for GLPGF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.24
Price
$118.63
GF Value